T-SPOT.<it>TB </it>responses during treatment of pulmonary tuberculosis
<p>Abstract</p> <p>Background</p> <p>Immune responses to <it>Mycobacterium tuberculosis </it>antigens could serve as surrogate markers of treatment response.</p> <p>Methods</p> <p>Using the T-SPOT.<it>TB </it>assay and fro...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2009-02-01
|
| Series: | BMC Infectious Diseases |
| Online Access: | http://www.biomedcentral.com/1471-2334/9/23 |
| _version_ | 1818530202210271232 |
|---|---|
| author | Conde Marcus B Chaisson Richard E Efron Anne Loredo Carla Hackman Judith Dooley Kelly Ribeiro Samantha Boechat Neio Dorman Susan E |
| author_facet | Conde Marcus B Chaisson Richard E Efron Anne Loredo Carla Hackman Judith Dooley Kelly Ribeiro Samantha Boechat Neio Dorman Susan E |
| author_sort | Conde Marcus B |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Immune responses to <it>Mycobacterium tuberculosis </it>antigens could serve as surrogate markers of treatment response.</p> <p>Methods</p> <p>Using the T-SPOT.<it>TB </it>assay and frozen peripheral blood mononuclear cells, we enumerated ESAT-6- and CFP-10-specific IFN-γ-producing T cells over time in pulmonary TB patients receiving directly observed treatment. T cell responses (measured as "spot forming cells" or "SFCs") were assessed prior to treatment and at 16 and 24 weeks of treatment.</p> <p>Results</p> <p>58 patients were evaluated, of whom 57 were HIV seronegative. Mean (SD) ESAT-6, CFP-10, and summed RD1 specific SFCs declined from 42.7 (72.7), 41.2 (66.4), and 83.8 (105.7) at baseline to 23.3 (39.4, p = 0.01), 23.2 (29.4, p = 0.18), and 46.5 (59.5, p = 0.02) at completion of 24 weeks of treatment, respectively. Only 10% of individuals with a baseline reactive test reverted to negative at treatment week 24. For the group that was culture positive at completion of 8 weeks of treatment compared to the culture negative group, the incidence rate ratio (IRR) of ESAT-6, CFP-10, and summed RD1 specific SFC counts were, respectively, 2.23 (p = 0.048), 1.51 (p = 0.20), and 1.83 (p = 0.047). Patients with cavitary disease had mean ESAT-6 specific SFC counts that were higher than those without cavitary disease (IRR 2.08, p = 0.034).</p> <p>Conclusion</p> <p>IFN-γ-producing RD1-specific T cells, as measured in the T-SPOT.<it>TB </it>assay, may be directly related to bacterial load in patients undergoing treatment for pulmonary TB. However, high inter-subject variability in quantitative results coupled with failure of reversion to negative of qualitative results in most subjects at treatment completion may limit the utility of this assay as a surrogate marker for treatment efficacy.</p> |
| first_indexed | 2024-12-11T17:16:44Z |
| format | Article |
| id | doaj.art-d9eae177be8442e7b88583129a4a3b8f |
| institution | Directory Open Access Journal |
| issn | 1471-2334 |
| language | English |
| last_indexed | 2024-12-11T17:16:44Z |
| publishDate | 2009-02-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Infectious Diseases |
| spelling | doaj.art-d9eae177be8442e7b88583129a4a3b8f2022-12-22T00:57:18ZengBMCBMC Infectious Diseases1471-23342009-02-01912310.1186/1471-2334-9-23T-SPOT.<it>TB </it>responses during treatment of pulmonary tuberculosisConde Marcus BChaisson Richard EEfron AnneLoredo CarlaHackman JudithDooley KellyRibeiro SamanthaBoechat NeioDorman Susan E<p>Abstract</p> <p>Background</p> <p>Immune responses to <it>Mycobacterium tuberculosis </it>antigens could serve as surrogate markers of treatment response.</p> <p>Methods</p> <p>Using the T-SPOT.<it>TB </it>assay and frozen peripheral blood mononuclear cells, we enumerated ESAT-6- and CFP-10-specific IFN-γ-producing T cells over time in pulmonary TB patients receiving directly observed treatment. T cell responses (measured as "spot forming cells" or "SFCs") were assessed prior to treatment and at 16 and 24 weeks of treatment.</p> <p>Results</p> <p>58 patients were evaluated, of whom 57 were HIV seronegative. Mean (SD) ESAT-6, CFP-10, and summed RD1 specific SFCs declined from 42.7 (72.7), 41.2 (66.4), and 83.8 (105.7) at baseline to 23.3 (39.4, p = 0.01), 23.2 (29.4, p = 0.18), and 46.5 (59.5, p = 0.02) at completion of 24 weeks of treatment, respectively. Only 10% of individuals with a baseline reactive test reverted to negative at treatment week 24. For the group that was culture positive at completion of 8 weeks of treatment compared to the culture negative group, the incidence rate ratio (IRR) of ESAT-6, CFP-10, and summed RD1 specific SFC counts were, respectively, 2.23 (p = 0.048), 1.51 (p = 0.20), and 1.83 (p = 0.047). Patients with cavitary disease had mean ESAT-6 specific SFC counts that were higher than those without cavitary disease (IRR 2.08, p = 0.034).</p> <p>Conclusion</p> <p>IFN-γ-producing RD1-specific T cells, as measured in the T-SPOT.<it>TB </it>assay, may be directly related to bacterial load in patients undergoing treatment for pulmonary TB. However, high inter-subject variability in quantitative results coupled with failure of reversion to negative of qualitative results in most subjects at treatment completion may limit the utility of this assay as a surrogate marker for treatment efficacy.</p>http://www.biomedcentral.com/1471-2334/9/23 |
| spellingShingle | Conde Marcus B Chaisson Richard E Efron Anne Loredo Carla Hackman Judith Dooley Kelly Ribeiro Samantha Boechat Neio Dorman Susan E T-SPOT.<it>TB </it>responses during treatment of pulmonary tuberculosis BMC Infectious Diseases |
| title | T-SPOT.<it>TB </it>responses during treatment of pulmonary tuberculosis |
| title_full | T-SPOT.<it>TB </it>responses during treatment of pulmonary tuberculosis |
| title_fullStr | T-SPOT.<it>TB </it>responses during treatment of pulmonary tuberculosis |
| title_full_unstemmed | T-SPOT.<it>TB </it>responses during treatment of pulmonary tuberculosis |
| title_short | T-SPOT.<it>TB </it>responses during treatment of pulmonary tuberculosis |
| title_sort | t spot it tb it responses during treatment of pulmonary tuberculosis |
| url | http://www.biomedcentral.com/1471-2334/9/23 |
| work_keys_str_mv | AT condemarcusb tspotittbitresponsesduringtreatmentofpulmonarytuberculosis AT chaissonricharde tspotittbitresponsesduringtreatmentofpulmonarytuberculosis AT efronanne tspotittbitresponsesduringtreatmentofpulmonarytuberculosis AT loredocarla tspotittbitresponsesduringtreatmentofpulmonarytuberculosis AT hackmanjudith tspotittbitresponsesduringtreatmentofpulmonarytuberculosis AT dooleykelly tspotittbitresponsesduringtreatmentofpulmonarytuberculosis AT ribeirosamantha tspotittbitresponsesduringtreatmentofpulmonarytuberculosis AT boechatneio tspotittbitresponsesduringtreatmentofpulmonarytuberculosis AT dormansusane tspotittbitresponsesduringtreatmentofpulmonarytuberculosis |